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Abstract
MicroRNAs (miRNAs) are small non-coding RNAs that function as regulators of gene expres-
sion. In recent years, there has been a tremendous and growing interest among researchers to in-
vestigate the role of miRNAs in normal cellular as well as in disease processes. Thus to investigate
the role of miRNAs in oral cancer, we analyse the expression levels of miRNAs to identify miRNAs
with statistically significant differential expression in cancer tissues.
In this article, we propose a novel Bayesian hierarchical model of miRNA expression data. Com-
pelling evidences have demonstrated that the transcription process of miRNAs in human genome is
a latent process instrumental for the observed expression levels. We take into account positional
clustering of the miRNAs in the analysis and model the latent transcription phenomenon nonpara-
metrically by an appropriate Gaussian process.
For the testing purpose we employ a novel Bayesian multiple testing method where we mainly
focus on utilizing the dependence structure between the hypotheses for better results, while also
ensuring optimality in many respects. Indeed, our non-marginal method yielded results in accor-
dance with the underlying scientific knowledge which are found to be missed by the very popular
Benjamini-Hochberg method.
Keywords: miRNA; Gaussian Process; GBSCC; Oral Cancer; Multiple Testing; Positional Clus-
tering.
1 Introduction
MicroRNAs (miRNAs) are small non-coding, single-stranded RNAs that function in the post-transcriptional
regulation of gene expression. There has been a tremendous and growing interest among researchers to
investigate the role of miRNA in normal as well as in disease processes over the last decade. Aberrant ex-
pressions of these tiny regulatory RNA molecules do have direct functional implications in carcinogenic
transformation or in further tumour progression towards lethal metastatic forms (Iorio and Croce, 2012;
Jansson and Lund, 2012). From rigorous genetic studies over the years it has been found that miRNAs
can function as both pro-tumorigenic and anti-tumorigenic molecules (Zhang et al., 2007; Shenouda and
Alahari, 2009) depending upon the genes which they target.
Considering the important role miRNAs play in tumorigenic processes, we try to identify and study
miRNAs which might play significant roles in head and neck carcinoma. According to WHO (2015),
a high percentage of Indian population are regular and direct tobacco users and tobacco users have a
significantly higher risk of cancer development. Gingivo buccal squamous cell carcinoma (GBSCC) is
one of the most prevalent among tobacco users and categorized as one of the most prominent type of head
and neck carcinoma as well. Head and neck squamous cell carcinoma stands as the fifth most common
malignancy worldwide (Jemal et al., 2005) and widely found among the tobacco users of India. Thus
we analyze miRNA expression data corresponding to cancer and normal tissues collected from GBSCC
patients.
We propose a new Bayesian hierarchical model in this paper for differential expressions of the
miRNAs harnessing information regarding their positional clustering. Subsequently we apply a novel
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Bayesian multiple testing methodology to detect miRNAs with statistically significant differential ex-
pressions. The specific data that we analyse in this context is detailed in Section 1.1 and in Section 1.2
we provide an overview of the Bayesian model and the multiple testing method that we employ in order
to detect significant miRNAs.
1.1 The data details
We used publicly available de-identified 18 patients’ 531 miRNA expression data from De Sarkar et al.
(2014). They generated these miRNA expression data from cancer tissues and normal tissues by a
high throughput real time polymerase chain reaction (RTPCR) assay (TaqMan Low Density Arrays
(TLDA), Applied Biosystems). Following the notations of Livak and Schmittgen (2001) we write, Ct =
Cycles at which the PCR product quantity reaches a defined threshold, ∆Ct = Centred Ct values
with respect to the geometric mean of expression of 3 most stable endogenous control miRNAs in that
tissue and ∆∆Ct = ∆Ctof a miRNA in cancer tissue − ∆Ct of that miRNA in control tissue. The ∆Ct values were
recorded for case and control tissues for the 531 miRNAs across the 18 patients to derive the ∆∆Ct
values. By design, some miRNA assays were done in duplicate; after the removal of such duplicates and
technical control miRNA data points, 522 unique miRNAs ∆∆Ct values or expression deregulation data
remained. It is important to note that, although the Ct values are positive, the ∆Ct values need not be
so as they are centred with respect to endogenous control. In this article, the ∆Ct value of each miRNA
is referred to its respective expression level. Now note that for some miRNA |∆∆Ct| > 1 implies that
the number of cycles needed to reach the predefined threshold is ±1 in cancer versus normal tissues.
Therefore the expression of the particular miRNA is 2 fold lower or higher in cancer tissues compared
to its paired normal. If a tumour has at least 2 fold relatively higher expression as compared to its normal
counterpart, it is usually referred to as up regulated (-1 or less ∆∆Ct value) and vice versa. Such up
and down regulation of a critical miRNA can be interpreted as a biologically significant deviation from
its normal quantity and could result in a possible significant functional impact.
1.2 A brief overview of our Bayesian hierarchical model and the multiple testing prob-
lem
Our interest lies in detecting those miRNAs that significantly influence the disease concerned in the
population, based on an appropriate and new Bayesian model, a novel multiple testing method, and the
available sample data set. We develop the model in three stages. We first propose an additive model
for the expression level of the miRNAs associated with Gaussian error terms in Section 2. In Section
3, we model the transcription process of the miRNAs by a latent Gaussian process instrumental for the
observed expression levels. Biological admissibility of such modelling is supported by a number of
studies discussed in the same section. The latent process also realistically accounts for the dependence
between the miRNAs that occurs in the course of the transcription process. In Section 4 we generalize
the model to account for miRNAs expressed from different strands of different chromosomes and also
formally state the multiple testing problem of interest. We also validate and check the goodness-of-
fit of the proposed model using leave-one-out cross-validation based on relevant posterior predictive
distributions.
In Section 5 we describe the novel Bayesian multiple testing method proposed by Chandra and
Bhattacharya (2017) to detect significantly deregulated miRNAs. In their multiple testing method, the
dependence structure between the miRNA is explicitly exploited. Application of their procedure to this
problem yielded insights and information that were unrevealed in the previous study of the same data
set by De Sarkar et al. (2014); the details are presented in Sections 6 and 7. Finally, we summarize our
contributions and make concluding remarks in Section 8.
2
2 Modelling the data and formulation of the multiple testing problem
Let Yj = (Yj1, . . . , Yjm)T be the ∆Ct values of m(= 522) miRNAs corresponding to cancer tissues
of the jth individual and Y˜j = (Y˜j1, . . . , Y˜jm)T be the ∆Ct values from the normal tissues of the same
individual, where the suffix T denotes transpose of the corresponding vector. We also assume that Yj
and Y˜j are both independently and identically distributed for j = 1, . . . , n(= 18), and that Yj and Y˜j
are independent of each other. Specifically, we assume that for j = 1, . . . , n and i = 1, . . . ,m,
Yji = θi + ji and Y˜ji = θ˜i + ˜ji, (1)
where θ = (θ1, . . . , θm)T and θ˜ = (θ˜1, . . . , θ˜m)T are the mean expression levels of the miRNAs for
case and control respectively and j = (j1, . . . , jm)T , ˜j = (˜j1, . . . , ˜jm)T are the random errors.
We assume that
j
iid∼ MN (0,Λm) and ˜j iid∼ MN (0, Λ˜m), (2)
and j , ˜j are independent for all j. In the above,MN (0,Λm) andMN (0, Λ˜m) stand for multivariate
(m-variate) normal with mean 0 (the m-component vector with all elements zero) and positive definite
covariance matrices Λm and Λ˜m, respectively.
We consider further dependence structure on θ and θ˜ by a bivariate Gaussian process to account
their inherent dependence structure. Also note that, in contrast with the usual white noise errors, here
we consider errors with dependence structures, which begs some explanation. This is discussed at the
end of Section 3.2.
3 Modelling the transcription process using bivariate Gaussian process
3.1 Motivation behind the latent process perspective
There has been quite substantial advancement in statistical modelling of miRNA expression data and
identification of differentially expressed miRNA genes. Clustering approaches have been extensively
used to find coexpressed genes. Genes in the same positional clusters are anticipated to be coexpressed
together. Clustered expression analysis of miRNAs also helps in detecting biomarkers which otherwise
would have been difficult due to the low intensity of their individual expression levels. Clustering of
genes often reduces complexity and also yields greater power. Detailed review on popular clustering-
based methods can be found in Wang et al. (2015); Conesa et al. (2016).
However, the existing methods do not take into account any dependence structure which occurs
through the transcription process of the miRNAs. Many of the miRNAs are located in the intronic
regions of host genes but may have their own promoter regions (Rupaimoole and Slack, 2017). Apart
from the intronic regions of protein coding genes miRNAs are commonly found to be located in the
clusters in the different intergenic regions of the genome (MacFarlane and R Murphy, 2010). Since
miRNAs are found to be in the genomic clusters their transcription might be regulated under the same
promoter and likely to be coexpressed as reported for a few miRNAs (Yang et al., 2008). Studies
demonstrate that expression levels of different genes are not merely random, but the neighbouring genes
in the genome have the tendency to be coexpressed together (Michalak, 2008). These studies provide fair
reasons to believe that transcription of the genes in the genome is not just a random phenomenon but are
subject to an underlying latent process. We believe that modelling the latent process and incorporating
it into the analysis is necessary to account for the dependence between genes in a more accurate way to
obtain reliable and interpretable results. In light of this discussion we propose and describe our approach
of modelling the transcription process of miRNAs.
3
3.2 Specifics of the bivariate Gaussian process modelling of the latent transcription pro-
cess
An important aspect of our modelling strategy, related to considering the transcription phenomenon as
a latent stochastic process, is incorporation of positional clusterings of the miRNAs and their genomic
coordinates into our model. miRNAs under the same positional cluster are likely to be coexpressed
together. Now it is to be noted that there are 22 pairs of autosomes (Chr1 through Chr22) and a pair
of sex chromosomes (XX/XY) in a human cell and each of them have two strands (we denote the two
strands by “+” and “-”). Thus there are 46 strands in total. As regards the discussion in the previous
section, miRNAs located close to each other on the genome, that is, neighbouring miRNAs located on
the same strand are expected to be regulated under the same promoter. Therefore, within each strand
nearby miRNAs can be regarded to be in the same positional cluster. To incorporate this biological
information statistically, we model the latent transcription process of miRNAs by a stationary Gaus-
sian process. In stationary Gaussian process structures, correlation between two miRNA expressions is
inversely proportional to their distance provided the miRNAs are expressed from the same strand.
For miRNAs lying in different chromosomes as well as in different strands of the same chromosome,
are not regulated by the same promoter. Therefore, the transcription processes of miRNAs for different
strands are considered independent and hence we do not put any dependence structure between the
strands a priori.
Now, θ and θ˜ in (1) are the mean expression levels of the miRNAs corresponding to case and control
tissues respectively. Since the case and control values for each miRNA are paired observations collected
from cancer and normal tissues of the same individual, a biological association should be present within
each pair. We account for this dependence, as well as the dependence between the miRNAs induced
by the transcription process, by assuming a bivariate Gaussian process (BGP) associated with θ and
θ˜ within each strand. For i = 1, . . . , k, where k = 46 is the total number of strands, consider the ith
strand and let θ(i)(x) and θ˜(i)(x) be the expression levels of the miRNA expressed from coordinate x of
the ith strand for case and control respectively. The genomic coordinates of the miRNAs were obtained
from miRBase (Griffiths-Jones et al., 2006). Then[
θ(i)(·)
θ˜(i)(·)
]
∼ BGP
(
M (i)(·), c(i)(·, ·), U (i)
)
, (3)
where, for any x, M (i)(·) =
[
µ(i)(·)
µ˜(i)(·)
]
is the bivariate mean function, U (i) is a 2 × 2 positive definite
matrix, and c(i)(·, ·) is a positive definite stationary covariance function. Since a priori information on
the mean functions µ and µ˜ are unavailable, we consider the same mean function for θ(i) and θ˜(i), that
is, we assume µ˜ = µ. As regards c(i)(·, ·), we have considered the Mate´rn covariance function here with
their own set of different hyperparameters for different strands. Technical details on BGP and Mate´rn
covariance function are briefly discussed in S-10.
Before we proceed to generalize our model, it is worth shedding light on an important aspect of our
model. Indeed, recall that in Section 2 we considered errors with dependence structures, rather than
the white noise error traditionally assumed. Note that the mean expression levels of the miRNAs asso-
ciated with different strands of the chromosomes are independent of each other as they are controlled
independently by different promoters. However, exploratory data analysis exhibited significant correla-
tion between the observed expression levels, even across the strands (see Figure 1). This suggests that
there are hitherto unexplored biological factors responsible for such correlations. The structured error
distributions account for such correlations, making the data dependent, within and across the clusters,
ensuring consistency with the exploratory analysis.
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Figure 1: Correlation heatmap of miRNA expressions.
4 Generalization of the model to account for miRNAs expressed from
different strands of different chromosomes
Chr1−

miR− 135b− 5p
miR− 181a− 5p
miR− 199a− 3p
miR− 194− 5p
. . .
Chr2−

miR− 194− 5p
miR− 216b− 5p
miR− 217
miR− 216b− 5p
. . .
ChrX−

let− 7f − 5p
miR− 106a− 5p
miR− 18b− 5p
miR− 19b− 3p
. . .
Chr9+

let− 7f − 1− 3p
miR− 181a− 5p
miR− 126− 5p
let− 7f − 5p
. . .
(4)
Notably, some miRNAs can be expressed from two or more genomic regions also (the coloured miRNAs
in (4) exhibit such instances). For such miRNAs, it is not possible to determine the exact expression level
corresponding to each region separately from the results of the PCR experiment. As a result we only have
total expression levels of the miRNAs in the dataset. For these types of miRNAs, we make some minor
modifications to the model. Let rl be the number of miRNAs in the lth strand and xl = (xl1 , . . . , xlrl )
be their corresponding coordinates in the genome. Note that the miRNAs which are transcribed from
several genomic locations also appear in more than one positional cluster according to their genomic
coordinates. Hence, the same miRNA is reported in multiple strands and therefore
∑k
l=1 rl = L > m.
Now consider miR − 181a − 5p as an illustrating example. Let Yji be its observed expression
level for the jth individual from case tissues. From (4) we see that it is transcribed from two genomic
locations. Let miR− 181a− 5p appear in the lth and the kth strand with genomic coordinates xlrl and
xkrk , respectively. Then we consider the following modification:
Yji = θ
(l)(xlrl ) + θ
(k)(xkrk ) + ji. (5)
In general, suppose a miRNA is in q strands and xl1 , · · · , xlq be the corresponding genomic coordi-
nates. Then
Yji = θ
(l1)(xl1) + · · ·+ θ(lr)(xlq) + ji. (6)
For miRNAs which are transcribed from some unique genomic location, we assume the following
model:
Yji = θ
(l)(xl) + ji. (7)
Let X = (xT1 , · · · ,xTk )T be the set of all coordinates of the miRNAs across all strands and let
θ(X) = (θ(1)(x1)
T , · · · ,θ(k)(xk)T )T be the corresponding mean expression levels, where for any
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l = 1, . . . , k, θ(l)(xl) = (θ(l)(xl1), . . . , θ
(l)(xlrl ))
T . Then
Yj = Pθ(X) + j , (8)
for a known matrix P of order m× L.
Similarly for expression levels corresponding to control tissues we have
Y˜j = P θ˜(X) + ˜j . (9)
However, we are mainly interested in identifying miRNAs which are significantly deregulated in case
tissues as compared to control tissues. Therefore, it is sufficient to work with the differential expressions
only, instead of dealing with both θ and θ˜. We define
Zj = Yj − Y˜j and ψ = P (θ(X)− θ˜(X)). (10)
Then Zj = ψ + τj where τj = j − ˜j .
Then in terms of ψ, in accordance with the objective discussed in Section 1.1, the hypothesis testing
problem can be framed as
H0i : |ψi| ≤ 1 versus H1i : |ψi| > 1, i = 1, . . . ,m. (11)
Working with differential expression values has certain advantages over considering both the case and
control values. Although it is not possible to infer about θ and θ˜ separately from the Z values, for the
testing problem (11), considering the Z values is sufficient (notably, Z values are actually the ∆∆Ct
values defined in Section 1.1). It not only simplifies the model, but also reduces the number of parame-
ters, thus significantly improving the performance of our Markov chain Monte Carlo (MCMC) strategy
discussed subsequently.
For the re-framed model (10), we need to obtain the distribution of θ− θ˜, where θ and θ˜ are associ-
ated with the bivariate Gaussian process. The following theorem, the proof of which is straightforward,
gives the desired distribution:
Theorem 4.1. Let θ and θ˜ be associated with a bivariate Gaussian process given by[
θ(·)
θ˜(·)
]
∼ BGP
([
µ(·)
µ(·)
]
, c(·, ·), U
)
. (12)
Define γ(x) = θ(x)− θ˜(x) for all x. Then
γ(·) ∼ GP (0, |U | × c(·, ·)) . (13)
where |U | is the determinant of U and GP is Gaussian process.
Following Theorem 4.1, we see that given the Mate´rn hyperparamaters σ,ν and ρ, ψ follows mul-
tivariate normal distribution a priori (details presented in S-11).
Now, recall that
Zj = ψ + τj and (14)
τj
iid∼ MN (0,Σ), where Σ = Λ + Λ˜, for all j = 1, . . . , n. (15)
Here Σ, %, ν, ρ all are unknown parameters. It is to be noted that
Zj |ψ,Σ iid∼ MN (ψ,Σ), (16)
that is, Σ is the conditional dispersion matrix of the Zjs. We put Inverse-Wishart prior on Σ. Appro-
priate prior distributions are also considered over the Mate´rn hyperparameters. In S-12, we discuss our
choice of prior distributions in detail.
Once the Bayesian hierarchical model is complete, samples from the posterior distribution of ψ
conditional on observed data Z requires to be generated to carry out the multiple hypothesis testing
problem in (11). We do this by the fast and efficient Transformation based Markov chain Monte Carlo
(TMCMC) method (Dutta and Bhattacharya, 2014). We also check the goodness-of-fit of our proposed
model by means of the leave-one-out cross-validation by computing appropriate posterior predictive
distribution. Details on the TMCMC method and goodness-of-fit results are discussed in S-13.
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5 A new Bayesian non-marginal multiple testing proposal
5.1 Motivation for non-marginal Bayesian multiple testing procedure
An analysis of the expression data is done by De Sarkar et al. (2014), though the transcription process
of the miRNAs was not considered in their model. They performed individual t-test for all the miRNAs
and applied the Benjamini-Hochberg (BH) method (Benjamini and Hochberg, 1995) for multiplicity
correction. The BH method is a p-value based procedure of multiplicity adjustment; however, in the
BH procedure, the dependence structure between the test statistics is not utilized. Although validity
of the BH procedure holds under positive dependence (Benjamini and Yekutieli, 2001), for negative
dependence the usefulness of BH is unclear.
Finner et al. (2007); Efron (2007) discussed the effect of dependence between test statistics, among
others. In Bayesian approaches, a natural dependence occurs between hypotheses through hierarchical
modelling and multiplicity correction is taken care of to some extent (Scott and Berger, 2010). Loss
function based approaches have been discussed by Mu¨ller et al. (2004). It is interesting that in the
aforementioned Bayesian works, positive dependence, unlike the popular BH procedure, is not required.
However, most of the multiple testing methods, either classical or Bayesian, primarily focus on
the validity of the test procedure in the sense of controlling FDR or oracle property corresponding
to some loss function, whereas exploiting the information provided by the dependence structure might
yield efficient closer to truth inference (Sun and Cai, 2009). When the decisions are not directly (de-
terministically) dependent, information provided by the joint structure inherent in the hypotheses are
somewhat neglected by the marginal multiple testing approaches, even though the data (and the prior in
the Bayesian case) possess dependence structure(s).
Keeping in mind the necessity of exploiting the dependence structure directly in the methodology, a
novel Bayesian non-marginal multiple testing procedure is devised by Chandra and Bhattacharya (2017).
The method, which is based on new notions of error and non-error terms, substantially enhances effi-
ciency by judicious exploitation of the dependence structure between the hypotheses. In this procedure
decisions regarding different hypotheses deterministically depend upon each other and hence the method
is referred to as the non-marginal procedure. The decision rule also has the desirable oracle property
corresponding to an additive “0-1” loss function (see Chandra and Bhattacharya (2017) for the details).
In Section 5.2 we discuss the Bayesian non-marginal procedure briefly.
5.2 An overview of the new Bayesian procedure for obtaining non-marginal decisions
5.2.1 The general multiple testing set-up
Let Z = (Z1, . . . ,Zn) be the observed data. Let the joint distribution of Z given ψ = (ψ1, . . . , ψm)T
be PZ|ψ(·) where ψ are the parameters of interest and ψi ∈ Θi for all i = 1, . . . ,m. We put a prior
Π(·) on the parameter space. Let Pψ|Z(·) and Eψ|Z(·) be the posterior probability and posterior expec-
tation of ψ, respectively, given Z. Here PZ(·) and EZ(·) represent the marginal distribution of Z and
expectation with respect to this marginal distribution, respectively.
Consider the following hypotheses:
H0i : ψi ∈ Θ0i versus H1i : ψi ∈ Θ1i,
where Θ0i
⋂
Θ1i = ∅ and Θ0i
⋃
Θ1i = Θi, for i = 1, . . . ,m. In this particular problem Θ0i = [−1, 1].
Here we discuss the multiple comparison problem in a Bayesian decision theoretic framework, given
data Zn. For i = 1, . . . ,m, let us first define the following quantities:
di =
{
1 if the ith hypothesis is rejected;
0 otherwise;
ri =
{
1 if H1i is true;
0 if H0i is true.
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5.2.2 New error based criterion
Let Gi be the set of hypotheses (including hypothesis i) whose decisions are highly dependent to that of
the ith hypothesis. Define the following quantity:
zi =
{
1 if Hdj ,j is true for all j ∈ Gi \ {i};
0 otherwise.
If Gi is a singleton, then we set zi = 1.
Now consider the term
TP =
m∑
i=1
dirizi. (17)
This is the number of cases i for which di = 1, ri = 1 and zi = 1; in words, TP is the number of
cases for which the ith decision correctly accepts H1i, and all other decisions in Gi, which may accept
either H0j or H1j , for j 6= i, are correct. We refer to this quantity as the number of true positives,
and maximize its posterior expectation with respect to d. But there are also errors to be controlled, and
Chandra and Bhattacharya (2017) advocated control of the following error:
E =
m∑
i=1
di(1− rizi), (18)
subject to maximizing TP .
Note thatE is the total number of cases i for which di = 1, rizi = 0, that is, either the ith hypothesis
is wrongly rejected or some other decision(s) in Gi is wrong, or both. This is regarded as the number of
false positives in our notion.
We will maximize the posterior expectation of TP given by (17) subject to controlling the posterior
expectation of E. Hence, with E to be controlled, the function to be maximized is given by
fβ(d) = Eψ|Z
[
m∑
i=1
di (rizi − β)
]
=
m∑
i=1
di (wi(d)− β) , (19)
where wi(d) = Eψ|Z [rizi] = Pψ|Z
(
H1i ∩ { ∩
j 6=i,j∈Gi
Hdj ,j}
)
and β is a constant lying in (0, 1).
Definition 5.1. Let D be the set of all m-dimensional binary vectors denoting all possible decision
configurations. Define
d̂ = argmax
d∈D
fβ(d),
where 0 < β < 1. Then d̂ is the optimal decision configuration obtained as the solution of non-marginal
multiple testing method.
It is to be noted that the performance of the non-marginal method heavily depends on the choice of
G1, . . . , Gm since the decisions regarding different hypotheses depend upon each other through the zi
terms defined in Section 5.2.2. Chandra and Bhattacharya (2017) provide detailed discussion regarding
this issue, following which the groups have been formed on the basis of prior correlation between the
parameters. Specifics on group formation are elaborated in S-14.1.
Analogous to Type-I and Type-II errors there also exist false discovery rate (FDR) and false non-
discovery rate (FNR) in multiple hypothesis testing. Sarkar et al. (2008) defined the posterior FDR
and FNR; we broadly adopt these definitions but significantly modify them in our Bayesian multiple
testing method to account for dependence between the hypotheses. Details on multiple testing error
measures are discussed in S-14.2.
8
6 Application of the Bayesian non-marginal multiple testing method to
the miRNA problem
We apply the non-marginal method to detect miRNAs with statistically significant differential expression
in cancer tissues as compared to normal tissues. Note that β in the definition of the non-marginal
procedure is the penalizing factor between Type-I and Type-II error. It balances between the posterior
expectations of TP and E. How much Type-I error is allowed to be incurred depends on the choice of
β. In this application we choose β such that posterior FDR ≈ 0.10. The estimated posterior FNR
based on the TMCMC samples is 0.04. The discoveries by the non-marginal method are shown in the
second column of Table 1 labelled by NMD. Out of a total of 522 miRNAs, the non-marginal method
has identified 12 miRNAs.
Table 1: List of significantly deregulated miRNAs
miRNA Method Deregulation BF ψˆi 95% CI of ψi
hsa-miR-129-2-3p NMD Up > 100 -2.11 (−2.95,−1.35)
hsa-miR-548k NMD Up 30.44 -1.77 (−2.47,−1.09)
hsa-miR-622 NMD Up > 100 -1.85 (−2.57,−1.13)
hsa-miR-147b NMD Up 2.75 -1.32 (−2.19,−0.56)
hsa-miR-124-3p NMD Up 0.32 -1.34 (−2.26,−0.45)
hsa-miR-130b-5p NMD Up 17.41 -1.94 (−2.78,−1.10)
hsa-miR-7-5p LRBH Up 0.03 -0.69 (−1.24, 0.67)
hsa-miR-31-3p LRBH Up 0.10 -0.76 (−1.23, 0.64)
hsa-miR-31-5p LRBH Up 0.06 -0.67 (−1.22, 0.64)
hsa-miR-133b NMD Down > 100 2.87 (2.02, 3.65)
hsa-miR-375 NMD Down 2.96 1.55 (0.73, 2.36)
hsa-miR-1249 NMD Down > 100 3.46 (2.61, 4.33)
hsa-miR-1 NMD, LRBH Down > 100 3.78 (2.96, 4.62)
hsa-miR-133a-3p NMD, LRBH Down > 100 4.36 (3.56, 5.22)
hsa-miR-206 NMD, LRBH Down > 100 4.59 (3.49, 5.51)
hsa-miR-204-5p LRBH Down 0.02 0.41 (−1.23, 0.63)
hsa-miR-1293
Declared significant by
De Sarkar et al. (2014)
Up 0.15 -0.87 (−1.24, 0.70)
6.1 Biological significances of the discoveries made by the non-marginal method
Most of the findings obtained by the non-marginal method have biological significance. hsa-miR-129-
2-3p is reported earlier to promote chemo-resistance in breast cancer (Zhang et al., 2015), and hsa-miR-
548k often triggers head and neck cancer by modifying TP53 gene (Gross et al., 2014). hsa-miR-147b is
reported to trigger head and neck squamous cell carcinoma with high statistical significance (Yata et al.,
2015), and hsa-miR-130b-5p is found to be upregulated in more than five cancer types (Mitra et al.,
2015). One of the target genes of hsa-miR-124-3p is ADIPOR2 which was reported to be negatively
associated with tumour progression in prostrate cancer (Hiyoshi et al., 2012).
hsa-miR-375 represses cell viability and proliferation via SLC7A11 in oral cancer (Wu et al., 2017).
The miRNA hsa-miR-1249 is known to regulate tumour growth via positive feedback loop of Hedgehog
signalling pathway (Ye et al., 2017). Both hsa-miR-1 and hsa-miR-133a-3p were reported earlier to
inhibit cell proliferation and induce apoptosis via TAGLN2 gene (Nohata et al., 2011; Kawakami et al.,
2012). hsa-miR-206 has been reported earlier as tumour suppressor (Song et al., 2009). Notably, the
last 3 miRNAs mentioned are also found to be significantly downregulated by De Sarkar et al. (2014).
hsa-miR-133b is significantly downregulated in our analysis and has been reported as tumour suppressor
in esophageal and gastric cancer (Kano et al., 2010; Qiu et al., 2014). This was not reported significant
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by De Sarkar et al. (2014), however, hsa-mir-1, hsa-mir-133a, hsa-mir-206 and hsa-mir-133b were re-
ported to be functionally related in human cancers (Nohata et al., 2012). This is a clear indication why
incorporating the dependence structure in biological data is important and ignoring which is likely to
lead to failure to detect important signals.
6.2 Results of testing the hypotheses using Bayes factor
Apart from applying the non-marginal multiple testing procedure, we also consider testing the hypothe-
ses using Bayes factor (BF). The BF is a summary of the evidence provided by the data in favour of
one scientific theory as compared to another, both represented by statistical models. It is often used to
compare competing models and Bayesian hypotheses. In multiple hypothesis testing problems, for the
ith hypothesis, the marginal Bayes factor is defined as
Bi =
Pψ|Z(Θ1i)
Pψ|Z(Θ0i)
× Π(Θ0i)
Π(Θ1i)
, (20)
that is, the ratio of posterior odds of H1i to its prior odds for all i = 1, . . . ,m. As summarized by Kass
and Raftery (1995), the evidence against H0i that is directed by the magnitude of Bi is shown in Table
2.
Table 2: Bayes factor summary
Bi Evidence against H0i
1 to 3.2 Not worth more than a bare mention
3.2 to 10 Substantial
10 to 100 Strong
> 100 Decisive
The BFs corresponding to the discoveries are shown in the 4-th column of Table 1. We see that
for most of the discoveries by the non-marginal method, BF indicates very strong evidence against H0.
However, in two cases the results of the non-marginal method, the BF based results and those reported
in the literature do not agree. Details follow.
Although hsa-miR-124-3p has been declared significant by the NMD method, the corresponding BF
shows evidence towardsH0 being true. Notably, BF provides evidence towards a belief but does not take
into account the multiplicity effect. On the other hand, the discoveries by the NMD procedure are the
results of proper FDR control. Controlling the FDR at a more conservative level would rule out the
miRNAs with low BFs as discoveries, however, sometimes at the cost of missing out important signals.
Hence, instead of such conservative approach, we recommend further biological investigation regarding
this discovery.
Previous biological research has reported hsa-miR-622 to be tumour suppressor in esophageal can-
cer (Song et al., 2016), though our analysis indicates upregulation. The discrepancy may also be due to
different tissue types where hsa-miR-622 have been reported to be downregulated in the literature. How-
ever, these findings are particularly interesting and further biological experiments should be conducted
with different groups of patients to find their roles in tumorigenic processes.
7 Comparison of our non-marginal results with those of the BH proce-
dure
Based on an independent normal model, De Sarkar et al. (2014) considered the BH multiplicity cor-
rection approach to identify the significant miRNAs. Before we compare their results with ours it is
important to discuss some methodological issues associated with computing the p-values needed for the
BH procedure.
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For the hypothesis testing problem defined in (11), the null hypothesis corresponding to each ψi is
composite and here even the marginal tests are not straightforward with the frequentist approach. To
mitigate this problem, De Sarkar et al. (2014) computed the sample medians of Zij ; j = 1, . . . , n,
say Z˜i. If Z˜i > 0 they tested H0i : ψi ≤ 1 versus H1i : ψi > 1, else they tested H0i : ψi ≥ −1
versus H1i : ψi < −1 for i = 1, . . . ,m, and obtained the corresponding p-values. In this way, each
composite test boils down to one-sided t-test by means of the monotone-likelihood property. However,
such separate tests based on the sign of the sample medians is not well-justified statistically as the results
of such tests may be non-negligibly different from those of the original composite tests of interest.
As a solution to the above problem, we propose the likelihood-ratio (LR) test for the original com-
posite hypothesis testing problem with respect to the same independent normal model. To obtain the
marginal p-values we implement a parametric bootstrap method and subsequently apply the BH adjust-
ment for multiplicity correction. We denote this newly implemented method by LRBH in this article.
The discoveries are shown in the second column of Table 1 labelled by LRBH. The discoveries by the
LRBH method are compared with the findings of the non-marginal method. The detailed comparison of
the results is provided in Section 7.1. The p-value approximation procedure is discussed in S-15.
7.1 Comparison of the results obtained by the LRBH and the non-marginal procedure
For comparability with the non-marginal method whose FDR is controlled at level 0.10, we control
the FDR of the LRBH procedure at level 0.10 as well. As summarized in Table 1, out of the 522
miRNAs, the LRBH method has identified 7 miRNAs as significant whereas the non-marginal method
has identified 12 miRNAs. Only three miRNAs, namely, hsa-miR-1, hsa-miR-133a-3p and hsa-miR-
206 turned out to be the common discoveries by the LRBH and the non-marginal procedure. It is thus
important to investigate the reasons for the discrepant findings, which we attempt below.
Note that the expression levels corresponding to different miRNAs including some of the discrepant
discoveries exhibit negative correlations (see Figures 1 and 2). In case of negatively correlated test
statistics validity of general BH procedure of multiplicity correction is not guaranteed theoretically.
Also from Section S-15 we see that no dependence between the test statistics has been considered and
working with only marginal p-values practically omits the correlation between the test statistics in the
analysis. Neglecting the correlation between test statistics might often leads to unstable inference (Qiu
et al., 2005).
However, in our Bayesian model, information across miRNAs are pooled and the dependence struc-
ture is exploited by means of hierarchical modelling. Not only that, the non-marginal method em-
ployed to detect statistically significant miRNAs directly takes into account the dependence structure
between dependent hypotheses, and the corresponding decisions deterministically depend upon each
other through the zi terms defined in Section 5.2.2. Extensive simulation studies show that this method
indeed performs better in dependent situations as compared to some popular methods (including BH)
and asymptotically minimizes the Kullback-Leibler divergence from the true model (Chandra and Bhat-
tacharya, 2017). Also for discoveries which are found significant by the BH method only, the Bayes
factors exhibit quite strong evidence towards H0 being true. Hence, we argue that in this application,
where the miRNAs possess inherent dependence structure, results yielded by the non-marginal method
are more reliable as compared to the BH procedure.
8 Summary and conclusion
To the best of our knowledge our attempt to constitute a Bayesian hierarchical model that realistically
accounts for case-control dependence and dependence among the miRNAs using the genomic coordi-
nates via a bivariate Gaussian process, is the first ever in the literature. Also first ever in the literature,
is the application of our Bayesian non-marginal multiple testing procedure that accounts for the de-
pendence among the hypotheses in a way that the decisions on the hypotheses are dependent on each
other and discovers miRNAs that hitherto seem to be unexplored. Indeed, the discoveries employing the
11
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Figure 2: Data exhibiting negative correlations among miRNA expressions.
non-marginal procedure with respect to this data differ significantly from those of the very popular BH
procedure applied in the context of a simple independent normal model. This vindicates the importance
of realistic modelling of the dependence structure and the associated realistic non-marginal Bayesian
multiple testing procedure. The BF based evidences are mostly in keeping with the non-marginal testing
results except hsa-miR-124-3p. As earlier discussed, performing stricter test will disregard the discov-
eries with low BF, but we do not recommend that.
Interestingly, all the 12 discoveries made by our non-marginal method are already flagged as sig-
nificant elsewhere in the literature. However, hsa-miR-622 turned out to be upregulated by our method
even though the literature suggests that both are downregulated. In this case, the BF also supports the
non-marginal method.
The above discussion points to the fact that the results associated with our Bayesian non-marginal
method are generally well-supported by the literature and the BF values. In realistic multiple testing situ-
ations where the number of hypotheses is much larger compared to the sample size, pooling information
across hypotheses exploiting their inherent dependence structure seems crucial for realistic inference.
The leave-one-out posterior predictive plots (S-6) suggest that the predictive prowess of our model is
excellent even with a very small training set. Hence, our approach of Bayesian hierarchical modelling
of miRNA expression data is well-supported.
Although further biological research is necessary to shed more light on the discrepant findings sum-
marized above, from the statistical perspective, incorporation of dependence structure in our Bayesian
model and the non-marginal testing method is the major cause for the discrepant discoveries. Indeed,
in our experience, taking account of the underlying dependence structure in the model and the testing
method is absolutely necessary for realistic inference in complex phenomena, as here.
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9 Code with Example and Instructions
The codes are available in the following link
https://goo.gl/N9AAbp.
Supplementary Material
S-10 Details on bivariate Gaussian process
We now elaborately explain the latent process and its distribution. For any arbitrary set of r miRNAs
in the ith strand, let Θ(i) =
[
θ(i)(x1), · · · , θ(i)(xr)
θ˜(i)(x1), · · · , θ˜(i)(xr)
]
be the 2 × k matrix of their expression levels,
the rows of which denote the expression values corresponding to case and control. Then Θ(i) follows a
matrix-variate normal (MVN ) distribution:
Θ(i) ∼MVN 2×r
(
M (i)(x1:r), U
(i)2×2, V (i)r×k(x1:r)
)
,
where
M (i)(x1:r) =
[
µ(i)(x1), · · · , µ(i)(xr)
µ˜(i)(x1), · · · , µ˜(i)(xr)
]
; (S-21)
V (i)(x1:r) = ((c
(i)(xj , xl)))r×r. (S-22)
In the above, (x1, . . . , xk) are the coordinates of the miRNA genes in the genome.
Let d be the distance between two locations xj and xl, say. Then, the Mate´rn covariance function is
given by
c(i)(xj , xj) = σ
(i)2; (S-23)
c(i)(xj , xl) = σ
(i)2 2
1−ν(i)
Γ(ν(i))
(√
2ν(i)
d
ρ(i)
)ν(i)
Kν(i)
(√
2ν(i)
d
ρ(i)
)
, (S-24)
where Γ(·) is the gamma function, Kν(i)(·) is the modified Bessel function of the second kind; σ(i), ρ(i)
and ν(i) are the non-negative parameters of the covariance function. Here σ(i)
2
is the process variance,
ν(i) is the smoothness parameter and ρ(i) is the correlation length. For different strands we allow the
hyperparameters to be different and denote the vector of hyperparameters by σ, ρ and ν, respectively.
Stein (2012) discussed why the Mate´rn class of covariance functions is generally recommended in spatial
models, following which we adopted the same.
The matrix normal distribution is related to the multivariate normal distribution (MN ) in the fol-
lowing way:
Θ(i) ∼MVN 2×k
(
M (i), U (i), V (i)
)
⇔ vec
(
Θ(i)
)
∼MN
(
vec
(
M (i)
)
, U (i) ⊗ V (i)
)
,
where ⊗ denotes the Kronecker product and vec (M) denotes vectorization of the matrix M . In the
above, U (i) is the covariance matrix of the columns and V (i) is the covariance matrix of the rows of
Θ(i). Matrix-normal distributions are particularly useful when there are reasons to believe that the
vector valued observations are not independent. In that situation U (i) takes into account the dependence
between the observations. Taking U (i) to be the identity matrix and the rows of M (i) to be identical
reduces the matrix normal realization to iid multivariate-normal realizations.
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It is to be noted that the covariance parameters of matrix-normal distribution are non-identifiable in
the sense that for any scale factor, s > 0, we have:
MVN 2×k
(
M (i), U (i), V (i)
)
≡MVN 2×k
(
M (i), sU (i),
1
s
V (i)
)
. (S-25)
A remedy to this identifiability problem is discussed by Glanz and Carvalho (2013). It is prescribed to
consider U and V as correlation matrices with diagonals as 1, that is,
U
(i)
jj = 1 and V
(i)
jj = 1, (S-26)
and to introduce a positive parameter σ to estimate the scale of the overall covariance. After this amend-
ment the re-parametrized model is:
vec
(
MVN 2×k
(
M (i), U (i), V (i);σ(i)
))
∼MN
(
vec
(
M (i)
)
, σ(i)
2
U (i) ⊗ V (i)
)
. (S-27)
Following this we also consider U (i) as a correlation matrix. The parameter σ(i) which is already embed-
ded in V (i) as a Mate´rn covariance function parameter, measures the scale of the covariance. A rigorous
study on matrix-normal distribution and its properties can be found in Gupta and Nagar (1999).
S-11 Discussion on prior distribution of the miRNA expression levels
The strand-wise bivariate Gaussian process assumption implies that θ(xi) has the multivariate normal
distribution with Mate´rn covariance given the hyperparameters. Specifically,
θ(i)(xi)|σ(i), ν(i), ρ(i) ∼MN
(
µ(i)(xi), V
(i)(xi)
)
. (S-28)
Provided a vector of locations xi, µ(i)(xi) and V (i)(xi) represents the mean vector and convariance
matrix of θ(i)(xi) respectively. Given the hyperparameters, our assumption of independence among the
strands makes the distribution of θ(X) multivariate normal with block-diagonal covariance matrix (see
Figure S-3). Indeed, with
Figure S-3: Block-diagonal covariance structure of θ(X).
µ =
(
µ(1)(x1), · · · , µ(k)(xk)
)T
; (S-29)
V = diag
(
V (1)(x1), · · · , V (k)(xk)
)T
, (S-30)
the distribution of θ(X) is given by
θ(X)|σ,ν,ρ ∼MN (µ,V ) . (S-31)
As we have considered the same mean function for θ and θ˜ a priori, the conditional distribution of
θ˜(X) given hyperparameters is the following:
θ˜(X)|σ,ν,ρ ∼MN (µ,V ) . (S-32)
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Since
(
θ(i)(·), θ˜(i)(·)
)T
are independent bivariate Gaussian process over the strand i, it follows that
γ(i)(·) = θ(i)(·)− θ˜(i)(·) are independent Gaussian processes GP (0, |U (i)| × c(i)(·, ·)) over the strands.
Note that the process variance of γ(i)(x) is |U (i)| × σ(i)2. Clearly, an identifiability problem arises here
between σ(i)
2
and |U (i)|. As a remedy to this problem we consider |U (i)| × σ(i)2 as a single parameter
%(i)
2
. Let
γ(X) = θ(X)− θ˜(X), (S-33)
that is, the vector of differential expression levels of the miRNAs across all strands. We define
W (i)(xl) = |U (i)| × V (i)(xl) and (S-34)
W = diag
(
W (1)(x1), · · · ,W (k)(xk)
)
. (S-35)
Note that, similar to V (i)(xi), W (i)(xi) is also a covariance matrix.
Then from Theorem 4.1 we have
γ(X)|%,ν,ρ ∼MN (0,W ) (S-36)
⇒ ψ|%,ν,ρ ∼MN (0,PWP T ). [∵ ψ = Pγ(X)] (S-37)
S-12 Prior distributions on the unknown parameters
S-12.1 Prior on Σ
The Inverse-Wishart distribution is a popular prior on unknown covariance matrices. It is also a conju-
gate prior for normal likelihoods. Hence, we consider Inverse-Wishart distribution as prior on Σ with
degrees of freedom υ and parameter-matrix δ2I .
[Σ] ∝ |δ2I|υ2 |Σ|−υ+m+12 e− 12 tr(δ2IΣ−1) ∝ δmυ|Σ|−υ+m+12 exp
{
−δ
2
2
tr(Σ−1)
}
. (S-38)
Here δ is the common scale parameter accounting for the variance of the Zjis. We put inverse-gamma
prior on δ2 and estimate the parameters of the inverse-gamma distribution by the empirical Bayes
method. This conjugacy allows Σ to be integrated out from the posterior distribution. As Σ is a p × p
order matrix (p = 522), integrating it out from the posterior density reduces the number of parame-
ters significantly. We have taken the degrees of freedom υ = p + 3 for a priori second order moment
existence.
S-12.2 Prior distributions on Mate´rn hyperparameters
It is to be noted that %, ν and ρ are all unknown positive parameters. As discussed in Gelman et al.
(2014), it is desirable that the prior distribution does not unduly influence the posterior distribution. As
such we put vague prior on these parameters, that is, locally uniform over a widespread range where
the true parameter is likely to lie. As %(1), . . . , %(k)’s are the strand-wise Gaussian process variances,
following the general practice we take the Inverse-Gamma (IG) prior on the %(i)s. The parameters of
the IG distribution are adjusted such that the mode of prior distribution is 1 and the variance is 100.
This prior gives positive probability to the positive part of the real line with maximum weight on 1; this
modal value can be regarded as the common a priori summary choice of variance (see Figure S-4a).
For the prior on ν(i), note that ν(i) determines the analytical smoothness of the Gaussian process
such that
(
θ(i)(x), θ˜(i)(x)
)T
is bν(i)c times mean-square differentiable, where b·c is the floor function.
In real data situations not much smoothness is to be expected. This belief is reflected more appropriately
by the log-normal prior compared to the gamma prior since the log-normal is thin tailed in comparison;
see Figure S-4b where we plot gamma and log-normal densities both with mode 1 and variance 100.
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Also observe that the large variance of the log-normal distribution allows even large values of ν(i) if the
data indicates so. As such, we consider the log-normal prior on ν(i) with mode 1 and variance 100.
To put a prior on ρ(i) we first need to analyse the role and interpretation of ρ(i) in the model. This
parameter is of the dimension of distance (Diggle and Ribeiro, 2007) and sometimes referred to as the
correlation length (Gneiting et al., 2010). In this light, the value of ρ(i) should approximately be the
length of the strand over which the observed miRNAs are expressed. We consider the mode of the prior
distribution of ρ(i)s to be the chromosomal length corresponding to strand i with variance 1000. Now
the length of genome is really high (generally in order of 108) and with such a large modal value and
high variance, the gamma and log-normal densities are almost the same (see Figure S-4c). Hence, taking
any of the distributions would practically be equivalent and we consider the log-normal prior for ρ(i).
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Figure S-4
The joint posterior density of ψ,ρ,ν,%2, δ2 given data Z is:
[ψ,ρ,ν,%2, δ2|Z] (S-39)
∝[Z|ψ, δ2]× [δ2]× [ψ|ρ,ν,%2]× [ρ]× [ν]× [%2] (S-40)
∝ exp
{−12ψ′(PWP T )−1ψ}
δmn
∣∣In + 1δ2 (Z −M)(Z −M)T ∣∣υ+n2 × [δ
2]× [ρ]× [ν]× [%2] (S-41)
whereM = ψT ⊗ 1n. Note that we have integrated out Σ from the likelihood. This not only simplifies
the likelihood but also reduces the number of parameters aiding the MCMC convergence.
S-13 Transformation based Markov chain Monte Carlo for sampling from
the posterior distribution and leave-one-out cross-validation for model
validation
S-13.1 Additive TMCMC method
TMCMC is employed to generate samples from the joint posterior distribution defined in (S-41). TM-
CMC is particularly useful for drawing samples from complex high-dimensional distributions. We now
briefly describe the additive TMCMC method, which is what we employ. Suppose one is interested in
sampling from the d-dimensional distribution with density pi(·). Let g(·) be an arbitrary density with
support R+, the positive part of the real line. We describe the algorithm in Algorithm 1.
It is important to note that all the variables are updated through a single  at each iteration and Dutta
and Bhattacharya (2014) discussed its advantages especially in high dimensions. Dey and Bhattacharya
(2017) discussed optimal scaling properties of the additive TMCMC algorithm described in Algorithm
1 where g(·) is a normal distribution with the negative part truncated, that is, g() ≡ N(0, 1)I>0 for op-
timal acceptance rate of the algorithm and also prescribed a methodology to obtain approximate optimal
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Algorithm 1 Additive TMCMC algorithm
1: Input: Initial value x0 = (x01, . . . , x0d), number of iterationsN and suitably chosen positive valued
scaling parameters c1, . . . , cd.
2: for t = 0 · · ·N do
3: Generate  ∼ g(·) and bi, i = 1, . . . , d where bi’s are iid random variables taking values +1 or
−1 with equal probability.
4: Set x∗ = (xt1 + b1c1, . . . , xtd + bdcd) and α(xt, ) = min
{
1, pi(x
∗)
pi(xt)
}
.
5: xt+1 =
{
x∗ with probability α(xt, )
xt with probability 1− α(xt, ).
scaling in practice. Following their prescription we have chosen the scaling parameters mentioned in
Step 1 of Algorithm 1 and generated samples from the distribution of our interest. As many as 1.5×108
samples were generated out of which the first 3 × 107 samples were discarded as burn-in. A TMCMC
sample is stored at every 100th iteration. Traceplots of some selected parameters shown in Figure S-5
provide evidence towards excellent mixing.
S-13.2 Model validation
To validate our proposed model we conduct leave-one-out cross-validation for each of the n data points
by successively excluding the ith (for i = 1, . . . , n) data point and computing the corresponding poste-
rior predictive distribution based on the remaining n − 1 data points. The posterior predictive distribu-
tions are also approximated by drawing samples by the TMCMC algorithm. In Figure S-6 we show the
results associated with four data points. The dark coloured region represents the 75% credible region
of the posterior predictive distribution of the Zij’s. We see that the true data point lies well within the
credible region in most of the cases, even though the 75% credible regions are much narrow compared
to the traditional 95% regions that are usually advocated in general Bayesian analysis as a rule of thumb.
On the basis of our leave-one-out posterior predictive results, we conclude that our postulated model
very ably explains the variability of the data.
S-14 Discussion on multiple testing methodology
S-14.1 Choice of G1, . . . , Gm
In Section 3.1, with proper biological motivation we have discussed that miRNAs generated from nearby
locations have high chance to be coexpressed together. Thus, it is natural to form groups with miRNAs
with nearby locations. Now as regards the statistical dependence among the miRNAs, we have consid-
ered the Mate´rn covariance function c(i)(·, ·) within strand i. Notably,
c(i)(xj , xl) ∝ 1|xj − xl|
for the genomic locations xj and xl where |xj − xl| is the distance between them. Thus forming groups
of miRNAs on the basis of genomic distance is equivalent to forming groups based on prior correlation.
In practice, we first estimate the prior correlation matrix of ψ from the model that we propose
using the Monte Carlo method. Let R be the correlation matrix with the (i, j) element rij . We then
consider the correlations between the ith and jth parameters, with i < j, and obtain the 95th percentile,
r, of these quantities. Then, in Gi we include only those indices j( 6= i) such that rij ≥ r. Thus,
the ith group contains indices of the parameters that are highly correlated with the ith parameter. If
there exists no index j such that rij ≥ r, then we set Gi = {i}. To reduce complexity we restrict the
groups to contain at most 5 indices associated with at most 5 largest values of rij exceeding r. This
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Figure S-5: Traceplots of TMCMC samples.
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strategy has produced excellent results in the simulation studies by Chandra and Bhattacharya (2017).
It was observed that limiting the group size to 5 increases the power without much affecting the method
complexity. Therefore we employ this strategy in this application as well.
S-14.2 Error measures in multiple testing
The False Discovery Rate (FDR) is defined as
FDR = EZ
[∑
d∈D
∑m
i=1 di(1− ri)
{∑mi=1 di} ∨ 1 δ(d|Z)
]
, (S-42)
where δ(d|Z) is the probability of choosing the decision configuration d according to the associated
multiple testing procedure given data Z. In case of non-randomized decision rules, δ(d|Z) = 1 for
the decision configuration which is chosen to be the final decision rule. Notably, given a particular data
set, the non-marginal procedure also gives a binary vector as the optimal decision configuration, not any
randomized decision rule.
Under the prior distribution of ψ, the posterior FDR is defined as :
posterior FDR =Eψ|Z
[∑
d∈D
∑m
i=1 di(1− ri)
{∑mi=1 di} ∨ 1 δ(d|Z)
]
=
∑
d∈D
∑m
i=1 di(1− vi)
{∑mi=1 di} ∨ 1 δ(d|Z). (S-43)
These can be regarded as measures of Type-I error in multiple testing. Similarly False Non-Discovery
Rate (FNR) stands as a measure of Type-II error. It is defined as:
FNR = EZ
[∑
d∈D
∑m
i=1(1− di)ri
{∑mi=1(1− di)} ∨ 1δ(d|Z)
]
, (S-44)
and the posterior FNR is
posterior FNR =Eψ|Z
[∑
d∈D
∑m
i=1(1− di)ri
{∑mi=1(1− di)} ∨ 1δ(d|Z)
]
=
∑
d∈D
∑m
i=1(1− di)vi
{∑mi=1(1− di)} ∨ 1δ(d|Z).
(S-45)
As error criteria in Bayesian multiple testing paradigm, Chandra and Bhattacharya (2017) advocated
controlling posterior versions of the errors. In keeping with the Bayesian philosophy, it makes sense
to control error measures conditional on the data, avoiding expectation with respect to the (marginal)
distribution of the data. Not only does this support the Bayesian philosophy, it also drastically simplifies
the computation of such error measures in complex practical problems. Fan and Han (2017) proposed a
methodology for estimating FDR under unknown arbitrary dependence. However, in their model there
is no dependence structure between the hypotheses a priori and they also assumed sparsity. Such as-
sumptions are not valid with respect to our realistic model and in general realistic composite hypothesis
testing problems like ours. On the other hand, the posterior versions are readily available from TMCMC
samples drawn from the posterior distribution. Therefore, we control posterior FDR and also estimate
posterior FNR for the obtained decision rule.
S-15 Approximation of the p-values for the composite hypothesis testing
problem
For BH adjustment of multiplicity correction, p-values are required corresponding to each hypothesis.
Note that
Zi1, . . . , Zin
iid∼ N (ψi, σ2i ), i = 1, . . . ,m.
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The likelihood is given by:
Li(ψi, σ
2
i ) =
n∏
j=1
f(Zij ;ψi, σ
2
i )
where f(·;ψi, σ2i ) is the density of a standard normal distribution with mean ψi and variance σ2i .
The LR-test statistics for the ith test is
ζi =
sup
ψi∈[−1,1],σ2i ∈R+
Li(ψi, σ
2
i )
sup
ψi∈R,σ2i ∈R+
Li(ψi, σ2i )
The corresponding p-value is given by:
pi = PH0i
(
ζi < ζ
(obs)
i
)
,
where ζ(obs)i is the observed value associated with the random variable ζi. The null distributions of the
ζi is not available in closed form and therefore we estimated pi using the bootstrap method and subse-
quently identified miRNAs with statistically significant differential expressions by the BH procedure.
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